Literature DB >> 1448092

Molecular cloning of cellular genes encoding retinoblastoma-associated proteins: identification of a gene with properties of the transcription factor E2F.

B Shan1, X Zhu, P L Chen, T Durfee, Y Yang, D Sharp, W H Lee.   

Abstract

The retinoblastoma protein interacts with a number of cellular proteins to form complexes which are probably crucial for its normal physiological function. To identify these proteins, we isolated nine distinct clones by direct screening of cDNA expression libraries using purified RB protein as a probe. One of these clones, Ap12, is expressed predominantly at the G1-S boundary and in the S phase of the cell cycle. The nucleotide sequence of Ap12 has features characteristic of transcription factors. The C-terminal region binds to unphosphorylated RB in regions similar to those to which T antigen binds and contains a transactivation domain. A region containing a potential leucine zipper flanked by basic residues is able to bind an E2F recognition sequence specifically. Expression of Ap12 in mammalian cells significantly enhances E2F-dependent transcriptional activity. These results suggest that Ap12 encodes a protein with properties known to be characteristic of transcription factor E2F.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1448092      PMCID: PMC360501          DOI: 10.1128/mcb.12.12.5620-5631.1992

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  67 in total

1.  DNA-binding activity of retinoblastoma protein is intrinsic to its carboxyl-terminal region.

Authors:  N P Wang; P L Chen; S Huang; L A Donoso; W H Lee; E Y Lee
Journal:  Cell Growth Differ       Date:  1990-05

2.  Cloning of cDNAs for cellular proteins that bind to the retinoblastoma gene product.

Authors:  D Defeo-Jones; P S Huang; R E Jones; K M Haskell; G A Vuocolo; M G Hanobik; H E Huber; A Oliff
Journal:  Nature       Date:  1991-07-18       Impact factor: 49.962

3.  The retinoblastoma gene functions as a growth and tumor suppressor in human bladder carcinoma cells.

Authors:  R Takahashi; T Hashimoto; H J Xu; S X Hu; T Matsui; T Miki; H Bigo-Marshall; S A Aaronson; W F Benedict
Journal:  Proc Natl Acad Sci U S A       Date:  1991-06-15       Impact factor: 11.205

4.  Single-step purification of polypeptides expressed in Escherichia coli as fusions with glutathione S-transferase.

Authors:  D B Smith; K S Johnson
Journal:  Gene       Date:  1988-07-15       Impact factor: 3.688

5.  A cellular protein that competes with SV40 T antigen for binding to the retinoblastoma gene product.

Authors:  S Huang; W H Lee; E Y Lee
Journal:  Nature       Date:  1991-03-14       Impact factor: 49.962

Review 6.  Molecular genetics of the retinoblastoma suppressor gene.

Authors:  R Bookstein; W H Lee
Journal:  Crit Rev Oncog       Date:  1991

7.  Amino-terminal domains of c-myc and N-myc proteins mediate binding to the retinoblastoma gene product.

Authors:  A K Rustgi; N Dyson; R Bernards
Journal:  Nature       Date:  1991-08-08       Impact factor: 49.962

8.  Expression of the RB gene under the control of MuLV-LTR suppresses tumorigenicity of WERI-Rb-27 retinoblastoma cells in immunodefective mice.

Authors:  J Sumegi; E Uzvolgyi; G Klein
Journal:  Cell Growth Differ       Date:  1990-05

9.  The regions of the retinoblastoma protein needed for binding to adenovirus E1A or SV40 large T antigen are common sites for mutations.

Authors:  Q J Hu; N Dyson; E Harlow
Journal:  EMBO J       Date:  1990-04       Impact factor: 11.598

10.  Retinoblastoma cancer suppressor gene product is a substrate of the cell cycle regulator cdc2 kinase.

Authors:  B T Lin; S Gruenwald; A O Morla; W H Lee; J Y Wang
Journal:  EMBO J       Date:  1991-04       Impact factor: 11.598

View more
  108 in total

1.  Distinct cellular factors regulate the c-myb promoter through its E2F element.

Authors:  M R Campanero; M Armstrong; E Flemington
Journal:  Mol Cell Biol       Date:  1999-12       Impact factor: 4.272

2.  Regulation of endogenous E2F1 stability by the retinoblastoma family proteins.

Authors:  F Martelli; D M Livingston
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-16       Impact factor: 11.205

Review 3.  Integration of the pRB and p53 cell cycle control pathways.

Authors:  C L Stewart; A M Soria; P A Hamel
Journal:  J Neurooncol       Date:  2001-02       Impact factor: 4.130

4.  In vivo and in vitro interaction between human transcription factor MOK2 and nuclear lamin A/C.

Authors:  Caroline Dreuillet; Jeanne Tillit; Michel Kress; Michèle Ernoult-Lange
Journal:  Nucleic Acids Res       Date:  2002-11-01       Impact factor: 16.971

5.  PPARgamma induces cell cycle withdrawal: inhibition of E2F/DP DNA-binding activity via down-regulation of PP2A.

Authors:  S Altiok; M Xu; B M Spiegelman
Journal:  Genes Dev       Date:  1997-08-01       Impact factor: 11.361

6.  Identification of positively and negatively acting elements regulating expression of the E2F2 gene in response to cell growth signals.

Authors:  R Sears; K Ohtani; J R Nevins
Journal:  Mol Cell Biol       Date:  1997-09       Impact factor: 4.272

7.  Positive and negative regulation of cell proliferation by E2F-1: influence of protein level and human papillomavirus oncoproteins.

Authors:  R M Melillo; K Helin; D R Lowy; J T Schiller
Journal:  Mol Cell Biol       Date:  1994-12       Impact factor: 4.272

8.  Cyclin A/CDK2 binds directly to E2F-1 and inhibits the DNA-binding activity of E2F-1/DP-1 by phosphorylation.

Authors:  M Xu; K A Sheppard; C Y Peng; A S Yee; H Piwnica-Worms
Journal:  Mol Cell Biol       Date:  1994-12       Impact factor: 4.272

9.  Complementary functions of E1a conserved region 1 cooperate with conserved region 3 to activate adenovirus serotype 5 early promoters.

Authors:  H K Wong; E B Ziff
Journal:  J Virol       Date:  1994-08       Impact factor: 5.103

10.  Oncogenic capacity of the E2F1 gene.

Authors:  D G Johnson; W D Cress; L Jakoi; J R Nevins
Journal:  Proc Natl Acad Sci U S A       Date:  1994-12-20       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.